Robots make it to the healthcare conference panel, reflecting the future potential of technology
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
CMOs showed an increasing reluctance to take on debt in 2022
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Subscribe To Our Newsletter & Stay Updated
